Department of Oncology, Hangzhou Cancer Hospital, Hangzhou, 310002, China.
School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
BMC Psychiatry. 2024 Oct 11;24(1):678. doi: 10.1186/s12888-024-06143-x.
Among patients with solid tumors, those with breast cancer (BC) experience the most severe psychological issues, exhibiting a high global prevalence of depression that negatively impacts prognosis. Depression can be easily missed, and clinical markers for its diagnosis are lacking. Therefore, this study in order to investigate the diagnostic markers for BC patients with depression and anxiety and explore the specific changes of metabolism.
Thirty-eight BC patients and thirty-six matched healthy controls were included in the study. The anxiety and depression symptoms of the participants were evaluated by the 17-item Hamilton Depression Scale (HAMD-17) and Hamilton Anxiety Scale (HAMA). Plasma levels of glial fibrillary acidic protein (GFAP) and lipocalin-2 (LCN2) were evaluated using enzyme linked immunosorbent assay, and plasma lactate levels and metabolic characteristics were analyzed.
This study revealed that GFAP and LCN2 may be good diagnostic markers for anxiety or depression in patients with BC and that plasma lactate levels are also a good diagnostic marker for anxiety. In addition, specific changes in metabolism in patients with BC were preliminarily explored.
在实体瘤患者中，乳腺癌（BC）患者经历最严重的心理问题，表现出高全球流行的抑郁，对预后产生负面影响。抑郁可能很容易被忽视，并且缺乏其诊断的临床标志物。因此，本研究旨在探讨诊断 BC 伴抑郁和焦虑患者的标志物，并探索代谢的具体变化。
本研究纳入了 38 例 BC 患者和 36 例匹配的健康对照者。采用 17 项汉密尔顿抑郁量表（HAMD-17）和汉密尔顿焦虑量表（HAMA）评估参与者的焦虑和抑郁症状。采用酶联免疫吸附试验评估血浆神经胶质纤维酸性蛋白（GFAP）和脂联素-2（LCN2）水平，分析血浆乳酸水平和代谢特征。
本研究表明，GFAP 和 LCN2 可能是 BC 患者焦虑或抑郁的良好诊断标志物，血浆乳酸水平也是焦虑的良好诊断标志物。此外，还初步探讨了 BC 患者代谢的特定变化。
